Filing Details
- Accession Number:
- 0001209191-15-060930
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2015-07-15 17:02:11
- Reporting Period:
- 2015-07-13
- Filing Date:
- 2015-07-15
- Accepted Time:
- 2015-07-15 17:02:11
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1178879 | Amicus Therapeutics Inc | FOLD | Pharmaceutical Preparations (2834) | 200422823 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1400973 | F John Crowley | C/O Amicus Therapeutics, Inc. 1 Cedar Brook Drive Cranbury NJ 08512 | Chairman & Ceo | Yes | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2015-07-13 | 7,750 | $15.01 | 91,249 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2015-07-13 | 7,750 | $15.01 | 83,499 | No | 4 | S | Direct | |
| Common Stock | Acquisiton | 2015-07-14 | 142,250 | $15.03 | 225,749 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2015-07-14 | 142,250 | $15.03 | 83,499 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Options (right to buy) | Disposition | 2015-07-13 | 7,750 | $0.00 | 7,750 | $4.16 |
| Common Stock | Stock Options (right to buy) | Disposition | 2015-07-14 | 142,250 | $0.00 | 142,250 | $4.16 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 142,250 | 2013-11-01 | 2019-11-16 | No | 4 | M | Direct |
| 0 | 2013-11-01 | 2019-11-16 | No | 4 | M | Direct |
Reported Non-Derivative Holdings
| Sec. Name | Remaning Holdings | Nature of Ownership | Explanation |
|---|---|---|---|
| Common Stock | 64,895 | Indirect | By Trust |
Footnotes
- The exercise of stock options and subsequent sale of common stock were made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 17, 2014.
- This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.00 to $15.06. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.00 to $15.06. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
- This price is the weighted average purchase price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.00 to $15.10. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price.
- This price is the weighted average sale price for the transactions reported on this line. The prices for the transactions reported on this line range from $15.00 to $15.10. The reporting person undertakes to provide, upon request, by the staff of the Securities and Exchange Commission, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.
Billionaire Hedge Funds
